

Invited Review

Extracellular matrix in renal cell carcinomas

J. Lohi¹, I. Leivo², J. Oivula¹, V.-P. Lehto³ and I. Virtanen¹

¹Department of Anatomy, Institute of Biomedicine, University of Helsinki, Helsinki,

²Department of Pathology, The Haartman Institute, Helsinki, and ³Department of Pathology, University of Oulu, Oulu, Finland

Summary. Extracellular matrix (ECM) may be divided into interstitial matrix and the basement membrane (BM). ECM influences a variety of epithelial cell behaviours, including proliferation, differentiation, and morphogenesis, maybe most widely studied in kidney morphogenesis. In carcinomas, including renal cell carcinomas (RCCs), these properties and interactions of cells with interstitial matrix and BM are disturbed. As a carcinoma with a tendency to spread to distant sites, RCC is an interesting target for the study of epithelial-stromal interactions. Among interstitial collagens, type VI collagen appears to be widely distributed in RCCs. Also EDA-fibronectin (EDA-Fn) as well as tenascin-C (Tn) are important stromal components especially in poorly differentiated carcinomas. BMs of RCC islets and those of tumor blood vessel endothelia may merge in poorly differentiated carcinomas. As a dynamic component of BMs, laminins (Ln) are important in kidney development and RCC progression. Type IV collagen and nidogen, other components of BMs in RCCs, are produced by stromal as well as epithelial cells. ECM proteins may function in RCC progression by binding and regulating the activity of growth factors e.g. transforming growth factor β 1 and basic fibroblast growth factor. Also the expression of cell surface receptors for ECM is disturbed in RCCs. At least α_v integrin (Int) and CD44 emerge in renal epithelial cells during malignant transformation. Papillary renal neoplasms differ from RCCs by cell adhesion receptor expression and BM composition as well as by ECM avascularity and capacity to bind growth factors, thus suggesting a distinct property for this renal tumor.

Key words: Extracellular matrix, Basement membrane, Integrins, Growth factors

Introduction

Solid tumours are composed of two distinct compartments: the malignant parenchymal cells and the surrounding stroma. The stroma provides the vascular

supply that tumours require to obtain nutrients, for gas exchange, and waste disposal (Yeo and Dvorak, 1995). The tumour stroma is composed of extracellular matrix (ECM) structural proteins, interstitial fluid as well as various cytokines and growth factors produced by stromal cells. The stroma contains endothelial cells, myofibroblasts, mast cells, histiocytes and variably inflammatory cells (Yeo and Dvorak, 1995).

ECM is an elaborate array of proteins and proteoglycans assisting in the organization of cells into complex organs. ECM components are assembled into various combinations, producing specific environments within tissues. ECM proteins are typically large glycoproteins such as fibronectin (Fn), interstitial collagens, elastin and tenascin (Tn) that assemble into fibrils or other complex macromolecular arrays (Gumbiner, 1996). ECM influences functions of the cells, and exerts its effects through a family of specific cell surface receptors. The most important receptors are integrins (Int), some cell surface proteoglycans and CD44 (Adams, 1997).

A specialized structure of ECM, the basement membrane (BM), is a thin sheet of proteins. BMs cover the basal surfaces of all epithelia (Merker, 1994) and are especially important in influencing epithelial cell polarity and differentiation, hence guiding the emergence of cellular phenotypes from embryonic development onwards (Timpl and Brown, 1996). BM is connected to cells by several cell surface receptors including Int family, which transduce signals from ECM to the cellular interior and vice versa (Mercurio, 1995; Adams, 1997). In the kidney glomerulus BM has a special function as a filtration barrier, in which the laminin (Ln) β 2 chain appears to play an important role (Noakes et al., 1995). In addition to the aforementioned functions of BM, it serves as a structural barrier between tissue compartments, for instance in carcinomas, by separating the parenchymal cells from the surrounding stromal compartment. In epithelia, BM is formed in cooperation by epithelial and mesenchymal cells (Timpl and Brown, 1996).

In carcinomas, the epithelial-stromal interactions undergo changes that alter the regulation of the growth and function of cells, tissues and organs. Stroma-derived factors and interactions between ECM and neoplastic cells play a role in tumour cell migration as well as

Offprint requests to: Dr. Jouni Lohi, Department of Anatomy, Institute of Biomedicine, P.O. Box 9 (Siltavuorenpenger 20 A), Helsinki University, Helsinki, Finland

proliferation (Yeo and Dvorak, 1995; Wernert, 1997). The importance of tissue architecture is suggested by recent results on breast carcinoma cells which demonstrate that as long as the tissue architecture is maintained, the phenotype can override the genotype (Weaver et al., 1997).

In this review, we will discuss the composition and significance of ECM in renal cell carcinomas (RCCs).

Histology of renal cell carcinomas

Five histological types of renal carcinomas have been distinguished: clear-cell, chromophilic (papillary), chromophobic, oncocytic, and collecting-duct (Bellini's duct) tumours (for a review, see Weiss et al., 1995). Clear-cell carcinomas are the most common (75 to 85 percent) and the most widely studied renal tumours (Motzer et al., 1996). Further on in this review, we will use the term renal cell carcinoma (RCC) as a synonym for clear cell type RCC.

RCC is defined as a tumour composed of mixtures of cells with clear and granular cytoplasm arranged in non-papillary formations. Parenchymal cells of RCCs are most often organized into sheets or broad trabeculae, separated by a richly vascular fibrous stroma (solid pattern), or arranged around central spaces (glandular pattern) or lining cysts. The proliferating cells may be spindle-shaped and in high-grade tumors may acquire a sarcomatoid appearance (Weiss et al., 1995).

Interstitial matrix of renal cell carcinomas

Many different types of collagens have been described, all composed of distinct α chains. Among interstitial collagens, type I collagen is most often assumed to be the cause of pathological fibrosis, but in the kidney it is rather deposited in minute amounts late in the fibrosis (Furness, 1996). A much more abundant component of fibrotic matrix in the kidney is type III collagen (Furness, 1996). In RCCs collagen types I and III were detected in stroma of ca. half of the specimens by Droz et al. (1994). Also type VI collagen is a component of the ECM of normal human kidney (Magro et al., 1996). The expression of type VI collagen undergoes changes during kidney development, and in the studies of Magro et al. (1996) it has been located in mature kidney to mesangium, intertubular interstitium, renal capsule and to the BMs of Bowman's capsule, tubules and collecting ducts and to a lesser extent to the BM of glomeruli. However, our immunofluorescence results differ distinctly from those of Magro et al. (1996), suggesting that type VI collagen is clearly expressed in BMs of glomeruli (Fig. 1A), and, on the other hand, we did not find it in the BMs of tubules and collecting ducts (Fig. 1B) (Footnote, Lohi et al., unpublished results). The difference in results may be due to a greater resolution of the immunofluorescence method used by us, in comparison to avidin-biotin-peroxidase complex technique used by Magro et al.,

(1996). Type VI collagen has been suggested to act as an anchoring component linking the epithelial BMs with the ECM in developing mesonephric structures (Magro et al., 1995), hence resembling in function type VII collagen in stratified and compound epithelia (Wetzels et al., 1991). The distribution of type VI collagen in RCCs has not been described in the literature. Our immunofluorescence staining results suggest that type VI collagen is widely distributed in the stroma of RCCs (Fig. 1C) and occasionally appears to be present also in BM of RCC cell nests (Fig. 1D).

Among non-collagenous ECM glycoproteins in carcinomas a special interest has been devoted to Fn and Tn-C. They are modular proteins produced as several isoforms by differential splicing of mRNA (Chiquet-Ehrismann, 1995; Ffrench-Constant, 1995).

Fn is an extensively studied ECM glycoprotein. Originally it was characterized as a glycoprotein lost upon transformation (Vaheri and Ruoslahti, 1974; Hynes et al., 1978; Vaheri and Mosher, 1978). Knock-out mice lacking Fn die during embryonic development (George et al., 1993). Cellular adhesion has been attributed to a major biological function of Fn. Fn may also be a potential regulator in cancer cell growth. A truncated 178 kD fragment of Fn has been suggested to function as an autologous growth-promoting substance in RCC cell cultures (Kochevar et al., 1992). On the other hand, an RCC cell line was stimulated to migrate in response to Fn (Grossi et al., 1992) and a chemotactic ability for Fn was suggested to correlate with the metastatic potential of cultured RCC cells (Murata et al., 1992).

The alternative splicing of Fn gene product produces two major Fn isoforms, named extradomain-A (EDA) and EDB Fns. An additional isoform is produced by differential glycosylation of the variable region and has been named as oncofetal Fn (Matsuura et al., 1989). In normal human renal tissue EDA-Fn is only scarcely expressed in endothelia of larger vessels and in the mesangial matrix (Laitinen et al., 1991), but its expression is greatly increased in diverse variants of inflammatory glomerular disease as well as in chronic rejection (Gould et al., 1992; Assad et al., 1993). EDB-Fn and oncofetal-Fn are expressed in developing kidney, but are absent in normal adult kidney (Laitinen et al., 1991). Their expression is upregulated in association with cellular proliferation and/or necrosis in pathological conditions of human glomeruli (Assad et al., 1993). EDA-Fn is widely distributed in the stroma of RCCs, while the other isoforms are expressed only scarcely (Lohi et al., 1995), but they are abundant in stromal tissue of some other carcinomas (Kaczmarek et al., 1994; Koukoulis et al., 1995). However, we have found all the aforementioned Fn isoforms in xenograft tumours of RCC cells, suggesting that stromal factors are responsible for the production of various Fn isoforms (Lohi et al., 1995).

Tn-C is a disulfide-linked hexamer expressed in many developing organs at sites of epithelial-mesenchymal interaction (Chiquet-Ehrismann, 1995). Tn-C is

present in a restricted pattern in mature tissues, but appears in diverse reactive conditions (Koukoulis et al., 1991) and in the stroma of various carcinomas (see, e.g. Howedy et al., 1990; Koukoulis et al., 1991; Natali et al., 1991; Soini et al., 1992; Ibrahim et al., 1993; Tiitta et al., 1993, 1994). Stromal Tn expression in carcinomas has often been correlated with the degree of inflammation present in the tissue (Natali et al., 1991; Tiitta et al., 1992, 1993; Moch et al., 1993). In the usual interstitial pneumonia it has been suggested to be a marker of poor prognosis (Kaarteenaho-Wiik et al., 1996).

The significance of Tn as a prognostic marker in carcinomas is under an intense study in several laboratories. Our studies have shown that the expression of Tn in the invasion border of early breast cancer correlates with a high risk of distant metastasis (Jahkola et al., 1996). On the other hand, the results of Shoji et al. (1993) suggested that the local production of Tn by carcinoma cells might be potential marker of favorable

prognosis. The biological function of Tn-C has been under discussion during recent years. Various roles for Tn-C in directing morphogenesis or functioning as anti-adhesive molecule or mitogen have been suggested (Erickson, 1993; Chiquet-Ehrismann, 1995). On the other hand, Saga et al. (1992) reported, based on Tn-C gene knockout experiments, that «mice develop normally without Tn».

In normal human kidney Tn-C is expressed strongly in the mesangial matrix, weakly in medullary and tubular interstitium and variably in Bowman's capsular area (Koukoulis et al., 1991; Gould et al., 1992; Truong et al., 1994, 1996). The expression of Tn-C is increased in inflammatory glomerular disease as well as in chronic rejection (Gould et al., 1992; Assad et al., 1993). In well differentiated RCCs, Tn-C is located to the BM zone and around blood vessels, whereas in poorly differentiated carcinomas Tn-C is widely distributed throughout the stromal compartment (Lohi et al., 1995). Interestingly,




Fig. 1. Immunoreactivity for type VI collagen is detectable in BM of glomerulus and in the tubular area of adult human kidney (A). The figure with the higher magnification clearly demonstrates that immunoreactivity for type VI collagen in tubular area of kidney is located to the interstitial matrix, but not to the BMs (B). A widely distributed immunoreactivity for type VI collagen is present in the stromal compartment of poorly differentiated (gradus 3, WHO) RCC (C). With higher magnification, immunoreactivity for type VI collagen is detectable in the interstitial matrix between carcinoma cell islets and occasionally also in the BMs of well differentiated RCC (gradus 1, WHO) (D). A, B, x 200; C, D, x 380

we have found that in the experimental xenograft tumours derived from RCC cells, Tn-C distribution is associated with the grade of differentiation of the tumours in the same way as in RCCs (Lohi et al., 1995). Among the two distinct isoforms of Tn-C (Erickson, 1993), the low molecular weight isoform appears to be predominant in RCCs (Lohi et al., 1995), while both isoforms are prominent in breast carcinomas (Howeedy et al., 1990).

Another protein of the Tn family, Tn-X, has been found in culture medium of renal carcinoma cells (Matsumoto et al., 1994). Tn-X is prominent in skeletal and heart muscle (Chiquet-Ehrismann, 1995), but as with Tn-C its functions remain to be elucidated. Our results suggest that unlike Tn-C, Tn-X is scarcely expressed in fetal tissues but emerges during maturation. In kidney, Tn-X is variably found in the interstitium and Bowman's capsule, but not in the mesangial matrix. RCCs appeared to be rather negative for Tn-X.

Basement membranes in renal cell carcinomas

BM discontinuities have generally been associated with malignancy in various types of carcinomas (for original studies see Albrechtsen et al., 1981; Barsky et al., 1983; for reviews, see Bosman, 1994; Flug and Köpf-Maier, 1995). Liotta and Stetler-Stevenson (1991) have proposed a three step theory for the invasion of carcinoma cells through BMs. The steps include: tumour cell attachment to the ECM, proteolysis of BM and tumour cell locomotion. On the other hand, both malignant invasive tumours with continuous BM as well as noninvasive tumours with highly defective BM have been described (See for reviews, Bosman, 1994; Flug and Köpf-Maier, 1995). In RCCs, discontinuity of BM is associated with a high grade of differentiation (Korhonen et al., 1992b).

Type IV collagen together with Ln forms the structural framework of BM. Type IV collagen is a trimeric protein and the most widely expressed type IV collagen trimer is composed of two $\alpha 1(\text{IV})$ chains and one $\alpha 2(\text{IV})$ chain (Hudson et al., 1993). The $\alpha 3(\text{IV})$ - $\alpha 6(\text{IV})$ chains have a more restricted tissue distribution, but are expressed in kidney. In the normal adult human kidney, the $\alpha 3(\text{IV})$ - $\alpha 6(\text{IV})$ chains were distributed to the Bowman's capsular BMs, distal tubular or collecting duct BMs and $\alpha 3(\text{IV})$ - $\alpha 5(\text{IV})$ chains additionally to the glomerular BM (Miner and Sanes, 1994; Yoshioka et al., 1994; Mårtensson et al., 1995; Ninomiya et al., 1995; Peissel et al., 1995; Lohi et al., 1997a).

The expression of collagen $\alpha 2_2\alpha 1(\text{IV})$ trimer in BMs of RCCs has been described in several studies (Korhonen et al., 1992b; Droz et al., 1994; Mårtensson et al., 1995; Lohi et al., 1997a). Interestingly, trimers containing collagen $\alpha 3(\text{IV})$ - $\alpha 6(\text{IV})$ chains are also present in most of the RCCs (Lohi et al., 1997a). Both RCC cells as well as stromal cells appear to be potential sources for production of collagen $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$ chains as recently suggested by us based on xenograft

experiments using species-specific antibodies (Lohi et al., 1997a). Collagen $\alpha 3(\text{IV})$ - $\alpha 6(\text{IV})$ chains were, however, not expressed in RCC-derived xenograft tumours (Lohi et al., 1997a).

Lns are trimeric BM proteins composed of three different polypeptide chains. The first Ln trimer was isolated from a mouse tumour, Engelbreth-Holm-Swarm tumour, from which the name EHS-Ln is derived (Chung et al., 1979; Timpl et al., 1979). Later, after more Ln trimers had been isolated, EHS-Ln was renamed Ln-1 (Burgeson et al., 1994). Presently, five different α chains as well as three β and three γ chains have been described and they are presumed to form at least 11 distinct trimers named Lns-1 to -11 (Burgeson et al., 1994; Timpl and Brown, 1996; Miner et al., 1997).

Lns are responsible for many BM functions; for instance, the establishment of epithelial cell polarity and induction of epithelial cell differentiation during development (Adams and Watt, 1993; Timpl and Brown 1996). The significance of Ln in epithelial cell polarization during morphogenesis was initially suggested in an *in vitro* tubulogenesis model by Klein et al. (1988) and its significance in tubule formation was implicated by antibody inhibition experiments in organ cultures by Sorokin et al. (1992). Lns have a tissue-specific distribution, and this distribution varies during development in various tissues (Klein et al., 1990; Adams and Watt, 1993; Engvall, 1993; Lohi et al., 1996a, 1997b; Virtanen et al., 1996, 1997). Changes in the expression of Ln chains during nephrogenesis have been studied especially widely. For example, in the glomerular BM Ln $\beta 2$ chain replaces Ln $\beta 1$ chain during development of human, mouse and rat nephron (Virtanen et al., 1995; Durbeej et al., 1996; Miner et al., 1997). Among different Ln α chains, loss of $\alpha 4$ and further loss of Ln $\alpha 1$ chain in glomerular BM during mouse nephrogenesis has been reported recently (Miner et al., 1997). Hence, Ln $\alpha 5$ chain is the only Ln α chain present in mature mouse glomerular BM (Miner et al., 1997). Interestingly, the developmental transition in Ln α and β chains has been suggested to be regulated independently of each other (Miner et al., 1997). Summarizing the variable expression of various Ln chains during mouse nephrogenesis, Miner et al. (1997) have suggested that Ln-1 ($\alpha 1\beta 1\gamma 1$), -3 ($\alpha 1\beta 2\gamma 1$), -8 ($\alpha 4\beta 1\gamma 1$), -9 ($\alpha 4\beta 2\gamma 1$), -10 ($\alpha 5\beta 1\gamma 1$), and -11 ($\alpha 5\beta 2\gamma 1$) trimers may be present transiently in developing glomerular BM. Among different mouse tubular segments, $\alpha 1$ is present primarily in proximal tubular BMs, $\alpha 2$ in a subset of corticomedullary tubular BMs, and $\alpha 5$ in all BMs (Miner et al., 1997). In human kidney, Ln-1 is present in all tubular BMs of adult human kidney (Virtanen et al., 1995), whereas Ln-5 is located to a thin segment of the loop of Henle (Lohi et al., 1996b). RCCs express at least Ln $\alpha 1$, $\beta 1$, $\beta 2$ and $\gamma 1$ chains in their BMs (Lohi et al., 1996b). RCCs variably produce different Ln chains in cell culture conditions as well as in xenograft tumours, and the regulation is at least partially realized by stromal factors (Lohi et al., 1996b).

Our recent immunostaining experiments for Ln and type IV collagen, both major BM components, have shown that occasionally in poorly differentiated RCCs it is not possible to differentiate BM structures of carcinoma cells from those of endothelial cells by resolution of the immunofluorescence microscope. Therefore, we have proposed that a merging of BMs of RCC cells and endothelial cells takes place in poorly differentiated RCCs (Lohi et al., 1996b, 1997a). In this respect, it is of interest that the RCCs have a tendency to spread by hematogenous route (Motzer et al., 1996). Hyaline globules (extracellular collections of amorphous material) in RCCs have recently been suggested to contain multilayered accumulation of BM material, Ln and type IV collagen (Gatalica et al., 1997).

Nidogen is a BM glycoprotein consisting of three globular domains (Timpl et al., 1983; Paulsson et al., 1986; Dziadek, 1995). Nidogen binds Ln to type IV collagen (Timpl and Brown, 1996). Nidogen has been demonstrated to be widely present in the various BMs of human kidney (Katz et al., 1991), but there are no reports describing the expression of nidogen in RCCs. Nidogen is suggested to be derived from mesenchymal cells only (Ekblom et al., 1994; Thomas and Dziadek, 1993). Our unpublished results suggest that some RCC cell lines are able to produce nidogen in culture conditions and in xenografts of nude mice (Oivula et al., in preparation). A basic structural proteoglycan of the BMs, heparan sulfate proteoglycan, is known to be present in the BMs of the RCCs (Droz et al., 1994).

Cell surface receptors for extracellular matrix in renal cell carcinomas

Perhaps the most important receptors for ECM proteins are Ints, which are transmembrane glycoproteins consisting of one α and one β subunit (Ruoslahti, 1991; Hynes, 1992). At least 16 α and 8 β subunits are known to exist (Streit et al., 1996; Varner and Cheresh, 1996). Ints are believed to play a role e.g. in signal transduction, gene expression, proliferation, apoptosis regulation, embryogenesis, inflammation, tumour progression and metastasis (Albelda and Buck, 1990; Schwartz et al., 1995; Varner and Cheresh, 1996). Although a wealth of changes in the expression of Ints in malignant transformation has been reported (Streit et al., 1996), it is notable that there do not appear to be any general changes found in different types of malignancies, or shared by, for instance, most carcinomas.

Different Ints are characteristically expressed in specific nephron segments in the human kidney. Among α subunits of Ints, α_2 Int subunit is expressed in distal tubules and collecting ducts, whereas α_3 subunit was located in distal tubules as well as glomerular podocytes. α_6 subunit is widely present in all tubules (Korhonen et al., 1990b). Among β Ints, β_3 Int has a more restricted distribution than β_1 Int (Korhonen et al., 1990a). $\alpha_2\beta_1$, $\alpha_3\beta_1$ and $\alpha_6\beta_1$ Int complexes are suggested to be

involved in glomerulogenesis, whereas the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ may only play minor roles (Korhonen et al., 1990b). An important role for α_3 Int but not for Int α_6 in branching morphogenesis in kidney development was recently shown by gene knockout experiments by Kreidberg et al. (1996) and Georges-Labouesse et al. (1996). These are results in some ways contradictory to antibody inhibition studies of Sorokin et al. (1990).

RCC cells are known to variably express among β_1 integrins α_3 , α_4 , α_5 , and α_6 Int subunits (Korhonen et al., 1992b; Droz et al., 1994; Tomita et al., 1995; Gilcrease et al., 1996; Rabb et al., 1996). Results from our laboratory suggested that a decreased expression of int α_6 subunits would correlate with increasing histological grade of human RCCs (Korhonen et al., 1992b), but this suggestion has later been challenged (Terpe et al., 1993; Droz et al., 1994). Int $\alpha_4\beta_1$ is not detectable in adult human kidney (Cosio et al., 1990; Korhonen et al., 1990b, 1992a; Simon and Mc Donald, 1990; Adler, 1992), but is transiently expressed in the uninduced, not yet condensed mesenchymal cells during early development (Korhonen et al., 1992a). However, it has been suggested that it is expressed in most of the metastatic RCCs (Tomita et al., 1995; Gilcrease et al., 1996). Furthermore, adhesion of RCC cells to human umbilical-vein endothelial cells was inhibited by antibodies to Int α_4 (or vascular cell adhesion molecule-1), suggesting that Int $\alpha_4\beta_1$ complex might play a role in the hematogenous spread of RCCs (Tomita et al., 1995). Int $\alpha_5\beta_1$ complex, which has been described to be weakly present on endothelial and mesangial cells in the normal kidney (Cosio et al., 1990; Adler, 1992) or totally absent as detected with several antibodies (Korhonen et al., 1992b), has been associated with metastatic RCCs or extrarenal invasion (Gilcrease et al., 1996).

A specially important biological role has been suggested for α_v Int subunit. α_v Int associates with multiple β subunits forming distinct heterotrimers. $\alpha_v\beta_3$ Int has been suggested to influence cellular proliferation (Varner and Cheresh, 1996). In the normal kidney α_v Int is localized to the glomeruli, Bowman's capsule and vascular endothelium (Patey et al., 1994; Rabb et al., 1996). Int $\alpha_v\beta_5$ is also located in glomerular epithelial cells and occasionally to Bowman's capsule. Focal expression has also been claimed to be present in tubular epithelial cells (Patey et al., 1994; Rabb et al., 1996). An increased expression of α_v Ints has often been correlated with increasing malignancy (Varner and Cheresh, 1996). The α_v Int is expressed in RCCs, but there is no agreement as to whether it is associated with the grade of malignancy (Korhonen et al., 1992b; Droz et al., 1994; Rabb et al., 1996).

CD 44 is a widely expressed cell surface glycoprotein with functions e.g. in lymphocyte homing and activation, hematopoiesis, cell migration, binding of certain cytokines to the endothelium, and tumour metastasis (Streit et al., 1996). The epithelial isoform of CD44 mediates cell-extracellular matrix interactions by

recognizing hyaluronic acid (Culty et al., 1990; Underhill, 1992). CD44 has been found to be lacking in tubular and glomerular epithelial cells in the human kidney and to be expressed only in the interstitial tissue (Gilcrease et al., 1996). However, part of the RCCs are known to express CD44 (Terpe et al., 1993; Gilcrease et al., 1996). The expression of CD44 has been associated with extrarenal invasion or with known metastases at the time of nephrectomy (Gilcrease et al., 1996), but does not show any correlation with RCC tumour grade (Terpe et al., 1993). On the other hand, clear cell type RCCs differ from chromophilic cell type variants by their expression of CD44 (Heider et al., 1996).

On the origin of renal cell carcinomas

The origin of RCC has been under continuous debate. Based on immunohistochemical studies on various cytoplasmic or cell membrane antigens both proximal (Holthöfer et al., 1983; Borowitz et al., 1986; Gröne et al., 1986; Oosterwijk et al., 1986, 1990) and distal (Fleming et al., 1985; Blouin et al., 1989; Korhonen et al., 1992b) tubular origins have been proposed for RCCs. Recently, BM components typical for distal tubular BM were found in RCCs (Mårtensson et al., 1995; Lohi et al., 1997a). However, the expression of various cellular or extracellular proteins in carcinomas may not necessarily reflect the properties of their cell of origin.

Papillary renal neoplasms were traditionally considered to be histological variants of the usual renal adenocarcinomas, despite characteristic features of this subtype. Recently, papillary neoplasms were found to have cytogenetic abnormalities markedly different from other renal adenocarcinomas, justifying their consideration as a distinct type of neoplasms (Kovacs, 1989). In line with cytogenetically distinctive features, we have described a distinctive BM composition in papillary renal neoplasms. In distinction from non-papillary RCCs, papillary renal neoplasms express Ln-5

and on the other hand lack α_3 , α_4 and α_6 collagen IV chains in their BMs (Lohi et al., 1996b, 1997a). The expression of Ln-5 mimics characteristics of the thin segment of the loop of Henle (Lohi et al., 1996b). However, it is more evident that papillary renal neoplasms are derived from collecting ducts as was suggested earlier based on morphological data (Mancilla-Jiménez et al., 1976). Ln-5 is a ligand for both $\text{Int } \alpha_6\beta_4$ (Borradori and Sonnenberg, 1996; Niessen et al., 1994) and $\alpha_3\beta_1$ (Carter et al., 1991; Zhang and Kramer, 1996). Interestingly, papillary renal neoplasms unlike RCCs are also immunoreactive for α_6 (Fig. 2A) and β_4 Int subunits (Fig. 2B) and one of our two tumor specimens was also positive for hemidesmosomal antigen-1 (data not shown). BMs of papillary renal neoplasms also differ from RCCs by their binding of fibroblast growth factor-7 (Friedl et al., 1997). Another interesting difference in papillary renal neoplasms in comparison to RCCs is their avascularity (Mancilla-Jiménez et al., 1976; Boczko et al., 1979). Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is a multifunctional cytokine playing a role e.g. in angiogenesis by stimulating endothelial cell proliferation (Senger et al., 1993). VPF mRNA has been reported to be lacking in papillary renal neoplasms, although it has been found in RCCs (Brown et al., 1993).

Spreading of renal cell carcinomas

RCC tends to invade the renal vein and the inferior vena cava, occasionally reaching the right atrium (Motzer et al., 1996). The cellular and molecular mechanisms functioning in RCC spread have been widely investigated. Based on experiments in three dimensional matrigel culture by Yang et al. (1990), RCC cells have been suggested to reorganize ECM in their immediate vicinity. High nuclear grade carcinoma cells have been suggested to be the most invasive in matrigel cultures (Yang et al., 1990).

Cytokines are important in the homing and migra-




Fig. 2. A polarized immunoreactivity for α_6 (A) and β_4 (B) integrins was detectable in the papillae of papillary renal neoplasm. x 300

tion of lymphocytes and adhesion between leukocytes and endothelium (Chin et al., 1990). Similar mechanisms may operate in the spread of malignant cells. *In vitro* invasion assay experiments by Yanase et al., (1995) have shown that tumour necrosis factor, interleukin-1 and interleukin-6 increase the invasiveness of RCC cells by assisting their attachment to endothelia. Treatment with the aforementioned cytokines increases the expression of vascular cell adhesion molecule-1 in endothelial cells, but does not affect type IV collagenolysis (Yanase et al., 1995). On the other hand, the invasiveness of RCC cells is affected by MAb to vascular cell adhesion molecule-1. The interaction of $\alpha_4\beta_1$ Int complex on the surface of the RCC cells with vascular cell-adhesion molecule-1 (VCAM-1) in endothelial cells is a potential candidate for a mechanism operating in hematogenous metastasis of RCCs, as discussed earlier in this review (Tomita et al., 1995). Interleukin-2 has been suggested to modify the expression of intercellular adhesion molecule-1 on leukemia blasts (Olive et al., 1991). Interleukin-2-transfected RCC cells are reported to have a decreased binding affinity to Fn, Ln, type IV collagen and vitronectin (Hathorn et al., 1994). Hence, the local production of high concentrations of interleukin-2 and interferon- α at the tumour site may directly alter the interaction between RCC cells and ECM as well as the invasive and metastatic phenotype of the tumor (Hathorn et al., 1994). On the other hand, α IFN and γ IFN have an antiproliferative effect for cultured RCC cells (Buszello, 1995).

The interaction between epithelial and mesenchymal cells is important for epithelial differentiation (see e.g. Fritsch et al., 1997; Plateroti et al., 1997). The mesenchymal fibroblasts also play an important role in various pathological conditions: e.g. in wound healing and fibrocontractive diseases (Desmoulière and Gabbiani, 1996). They have also been involved in invasion and metastatic process: e.g. in colorectal carcinomas (Martin et al., 1996). Experiments with RCC cells have suggested that kidney -derived fibroblasts regulate their production of degradative enzymes (Gohji et al., 1994). Hence, fibroblasts may influence the invasive and metastatic capacity of RCC cells (Gohji et al., 1994).

ECM or BM proteins may also function in RCC spread also by binding distinct cytokines e.g. growth factors. The regulation of the activity of growth factors is mostly based on their binding to ECM, and rapid extracellular signaling is generated by proteolytic release and activation of stored growth factors (Taipale and Keski-Oja, 1997). For example, basic fibroblast growth factor has been suggested to interact with ECM and BM (Folkman, 1988; Flaumenhaft et al., 1989). Basic fibroblast growth factor is a pleiotropic growth factor, which is important in kidney development (Karavanova et al., 1996). Basic fibroblast growth factor has been suggested to play a role in growth and metastasis of various tumours (Nguyen et al., 1994). It is also a potent regulator in RCC spread (Duensing et al., 1995). Cytoplasmic expression of fibroblast growth factor has been

suggested to be a marker of poor prognosis in RCC (Nanus et al., 1993) and increased serum basic fibroblast growth factor levels have been reported to be associated with a higher frequency of progressive pulmonary metastases (Duensing et al., 1995).

Hepatocyte growth factor/scatter factor is a multi-functional effector of cells expressing c-met receptor in their cell membrane (Jeffers et al., 1996). Hepatocyte growth factor is involved in various cellular and tissue processes including kidney development (Santos et al., 1994; Woolf et al., 1995). The c-met/hepatocyte growth factor receptor has been suggested to be overexpressed in the RCCs. It is also overexpressed in the RCC cell line, the motility of which is triggered by HGF in invasion chamber model (Natali et al., 1996). Sulfoglycolipids on RCC cells might function as reservoirs for HGF (Kobayashi et al., 1994a). HGF stimulates the proliferation and motility of RCC cells, suggesting that HGF has multiple biological activities in RCC cells (Kobayashi et al., 1994b).

Transforming growth factor β is secreted from cells in latent form with propeptide, and it is activated later (Taipale and Keski-Oja, 1997). Transforming growth factor β is thought to associate with ECM and BM and its active form is suggested to be bound e.g. to type IV collagen and fibronectin (Taipale and Keski-Oja, 1997). Transforming growth factor β 1 has been considered as G1 phase-arresting inhibitory growth regulator for epithelial cells (Reddy et al., 1994). Transforming growth factor was suggested to suppress growth of two RCC cell lines *in vitro* (Wade et al., 1992). In the later experiments with 30 RCC cell lines, Ramp et al. (1997) found transforming growth factor β 1-resistant cells, and concluded that transforming growth factor β 1 resistance is an important factor for tumor progression in RCC.

Extracellular matrix remodelling

Some proteolytic remodelling of the ECM inevitably takes place during malignant progression of carcinomas (Liotta and Stetler-Stevenson, 1990), and among proteases, the matrix metalloproteases have been shown to present an altered distribution and activity in malignant tissues (Coussens and Werb, 1996). One of the functions for endogenous growth factors produced by carcinoma cells could be to induce the invasiveness or metastatic potential of cancer by increasing the production of degradative enzymes. Epidermal growth factor, which has a wide spectrum of activities including mitogenic, chemotactic and angiogenic effects (Khazaie et al., 1993) was reported to modulate the *in vitro* invasion, motility, and adhesiveness of RCC cells (Price et al., 1996). Additionally, epidermal growth factor increases their production of 92 kDa metalloproteinase (MMP-9; Price et al., 1996). On the other hand, overexpression of endogenous native fibroblast growth factor-2 has been suggested to play a role in the invasion and metastasis of renal cell carcinoma, through the production of MMP-2 (Miyake et al., 1996).

Gelatinase (MMP-2) production by RCC cells is influenced by organ microenvironment. Basic fibroblast growth factor, hepatocyte growth factor, and transforming growth factor β_1 appear to stimulate gelatinase expression by the cultured RCC cells. Kidney fibroblasts regulate by production of transforming growth factor β_1 the production of degradative enzymes by RCC cells (Gohji et al., 1994).

Acknowledgements. We thank Outi Rauanheimo for secretarial assistance

References

- Adams J.C. (1997). Cell adhesion- spreading frontiers, intricate insights. *Trends Cell Biol.* 7, 107-110.
- Adams J.C. and Watt F.M. (1993). Regulation of development and differentiation by extracellular matrix. *Development* 117, 1183-1198.
- Adler S. (1992). Integrin receptors in the glomerulus: potential role in glomerular injury. *Am. J. Physiol.* 262, F697-F704.
- Albelda S.M. and Buck C.A. (1990). Integrins and other cell adhesion molecules. *FASEB J.* 4, 2868-2880.
- Albrechtsen R., Nielsen M., Wewer U., Engvall E. and Ruoslahti E. (1981). Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. *Cancer Res.* 41, 5076-5081.
- Assad L., Schwartz M.M., Virtanen I. and Gould V.E. (1993). Immunolocalization of tenascin and cellular Fibronectins in diverse glomerulopathies. *Virchows Arch. (B)* 63, 307-316.
- Barsky S.H., Siegal G.P., Janotta F. and Liotta L.A. (1983). Loss of basement membrane components by invasive tumors but not by their benign counterparts. *Lab. Invest.* 49, 140-147.
- Blouin P., Guiot M.C. and Jothy S. (1989). Definition of the human renal cell carcinoma phenotype using monoclonal and polyclonal antibodies. A tumor marker study. *Exp. Pathol.* 36, 147-163.
- Boczko S., Fromowitz F.B. and Bard R.H. (1979). Papillary adenocarcinoma of the kidney. *Urology* 14, 491-495.
- Borowitz M.J., Weiss M.A., Bossen E.H. and Metzgar R.S. (1986). Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens. *Cancer* 57, 251-256.
- Borradori L. and Sonnenberg A. (1996). Hemidesmosomes: roles in adhesion, signaling and human diseases. *Curr. Opin. Cell Biol.* 8, 647-656.
- Bosman F.T. (1994). The borderline: Basement membranes and the transition from premalignant to malignant neoplasia. *Microsc. Res. Tech.* 28, 216-225.
- Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F. and Senger D.R. (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. *Am. J. Pathol.* 143, 1255-1262.
- Burgeson R.E., Chiquet M., Deutzmann R., Ekblom P., Engel J., Kleinman H., Martin G.R., Meneguzzi G., Paulsson M., Sanes J., Timpl R., Tryggvason K., Yamada Y. and Yurchenko P.D. (1994). A new nomenclature for the laminins. *Matrix Biol.* 14, 209-211.
- Buszello H. (1995). Antiproliferative effects of four different cytokines on renal carcinoma cell lines. *Anticancer Res.* 15, 735-738.
- Carter W.G., Ryan M.C. and Gahr P.J. (1991). Epiligrin, a new cell adhesion ligand for integrin $\alpha 3\beta 1$ in epithelial basement membranes. *Cell* 65, 2379-2384.
- Chin Y.H., Cai J.P. and Johnson K. (1990). Lymphocyte adhesion to cultured Peyer's patch high endothelial venule cells is mediated by organ-specific homing receptors and can be regulated by cytokines. *J. Immunol.* 145, 3669-3677.
- Chiquet-Ehrismann R. (1995). Tenascins, a growing family of extracellular matrix proteins. *Experientia* 51, 853-862.
- Chung A.E., Jaffe R., Freeman I.L., Vergnes J.P., Braginsk J.E. and Carlin B. (1979). Properties of a basement membrane related glycoprotein synthesized by a mouse embryonal carcinoma-derived cell line. *Cell* 16, 277-287.
- Cosio F.G., Sedmak D.D. and Nahman N.S. Jr. (1990). Cellular receptors for matrix proteins in normal human kidney and human mesangial cells. *Kidney Int.* 38, 886-895.
- Coussens L.M. and Werb Z. (1996). Matrix metalloproteinases and the development of cancer. *Current Biol.* 3, 895-904.
- Culty M., Miyake K., Kincade P.W., Silorski E., Butcher E.C. and Underhill C. (1990). The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. *J. Cell Biol.* 111, 2765-2774.
- Desmoulière A. and Gabbiani G. (1996). The role of the myofibroblast in wound healing and fibrocontractive diseases. In: *The molecular and cellular biology of wound repair*. 2nd ed. Chap. 13. Clark R.A.F. (ed). Plenum Press. New York. pp 391-423.
- Droz D., Patey N., Paraf F., Chrétien Y. and Gogusev J. (1994). Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors. *Lab. Invest.* 71, 710-718.
- Duensing S., Grosse J. and Atzpodien J. (1995). Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. *Anticancer Res.* 15, 2331-2334.
- Durbecq M., Fecker L., Hjalt T., Zhang H.-Y., Salmivirta K., Klein G., Timpl R., Sorokin L., Ebendal T., Ekblom P. and Ekblom M. (1996). Expression of laminin $\alpha 1$, $\alpha 5$ and $\beta 2$ chains during embryogenesis of the kidney and vasculature. *Matrix Biol.* 15, 397-413.
- Dziadek M. (1995). Role of laminin-nidogen complexes in basement membrane formation during embryonic development. *Experientia* 51, 901-913.
- Ekblom P., Ekblom M., Fecker L., Klein G., Zhang H.-Y., Kadoya Y., Chu M.-L., Mayer U. and Timpl R. (1994). Role of mesenchymal nidogen for epithelial morphogenesis *in vitro*. *Development* 120, 2003-2014.
- Engvall E. (1993). Laminin variants: Why, where and when? *Kidney Int.* 43, 2-6.
- Erickson H.P. (1993). Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. *Curr. Opin. Cell Biol.* 5, 869-876.
- Ffrench-Constant C. (1995). Alternative splicing of fibronectin - Many different proteins but few different functions. *Exp. Cell Res.* 221, 261-271.
- Flaumenhaft R., Moscatelli D., Saksela O. and Rifkin D.B. (1989). Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. *J. Cell Physiol.* 140, 75-81.
- Fleming S., Lindop G.B.M. and Gibson A.A.M. (1985). The distribution of epithelial membrane antigen in the kidney and its tumors. *Histopathology* 9, 729-739.

ECM in renal cell carcinomas

- Flug M. and Köpf-Maier P. (1995). The basement membrane and its involvement in carcinoma cell invasion. *Acta Anat.* 152, 69-84.
- Folkman J., Klagsbrunn M., Sasse J., Wadzinski M., Ingber D. and Vodavsky I. (1988). A heparin-binding angiogenic protein-basic fibroblast growth factor- is stored within basement membrane. *Am. J. Pathol.* 130, 393-400.
- Fox J.W., Mayer U., Nischt R., Aumailley M., Reinhardt D., Wiedemann H., Mann K., Timpl R., Krieg T., Engel J. and Chu M.-L. (1991). Recombinant nidogen consist of three globular domains and mediates binding of laminin to collagen type IV. *EMBO J.* 10, 3137-3146.
- Friedl A., Chang Z., Tierney A. and Rapraeger A.C. (1997). Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulphate. *Am. J. Pathol.* 150, 1443-1455.
- Fritsch C., Simon-Assmann P., Keding M. and Evans G.S. (1997). Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine. *Gastroenterology* 112, 826-838.
- Furness P.N. (1996). Extracellular matrix and the kidney. *J. Clin. Pathol.* 49, 355-359.
- Gatalica Z., Miettinen M., Kovatich A. and McCue P.A. (1997). Hyaline globules in renal cell carcinomas and oncocytomas. *Hum. Pathol.* 28, 400-403.
- George E.L., Georges-Labouesse E.N., Patel-King R.S., Rayburn H. and Hynes R.O. (1993). Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. *Development* 119, 1079-1091.
- Georges-Labouesse E., Messaddeq N., Yehia G., Cadalbert L., Dierich A. and Le Meur M. (1996). Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. *Nature Genet.* 13, 370-373.
- Gilcrease M.Z., Truong L. and Brown R.W. (1996). Correlation of very late activation integrin and CD 44 expression with extrarenal invasion and metastasis of renal cell carcinomas. *Hum. Pathol.* 27, 1855-1360.
- Gohji K., Nakajima M., Fabra A., Bucana C.D., von Eschenbach A.C., Tsuruo T. and Fidler I.J. (1994). Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. *Jpn J. Cancer Res.* 85, 152-160.
- Gould V.E., Martinez-Lacabe V., Virtanen I., Sahlin K.M. and Schwartz M.M. (1992). Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. *Lab. Invest.* 67, 71-79.
- Grossi F.S., Keizer D.M., Saracino G.A., Erkens S., Romijn J.C. and Schroder F.H. (1992). Flow cytometric analysis and motility response to laminin and fibronectin of four new metastatic variants of the human renal cell carcinoma line RC43. *Prog. Clin. Biol. Res.* 378, 195-205.
- Gröne H.J., Weber K., Helmchen U. and Osborn M. (1986). Villin: A marker of brush border differentiation and cellular origin in human renal cell carcinoma. *Am. J. Pathol.* 124, 294.
- Gumbiner B.M. (1996). Cell adhesion: the molecular basis of tissue architecture and morphogenesis. *Cell* 84, 345-357.
- Hathorn R.W., Tso C.-L., Kaboo R., Pang S., Figlin R., Sawyers C., deKernion J.B. and Belldegrun A. (1994). *In vitro* modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. *Cancer* 74, 1904-1911.
- Heider K.-H., Ratschek M., Zatloukal K. and Adolf G.R. (1996). Expression of CD44 isoforms in human renal cell carcinomas. *Virchows Arch.* 428, 267-273.
- Holthöfer H., Miettinen A., Paasivuo R., Lehto V.P., Linder E., Alfthan O. and Virtanen I. (1983). Cellular origin and differentiation of renal carcinomas. A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins. *Lab. Invest.* 49, 317-323.
- Howeedy A.A., Virtanen I., Laitinen L., Gould N.S., Koukoulis G.K. and Gould V.E. (1990). Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. *Lab. Invest.* 63, 798-806.
- Hudson B.G., Reeders S.T. and Tryggvason K. (1993). Type IV collagen: Structure, gene organization, and role in human diseases. *J. Biol. Chem.* 268, 26033-26036.
- Hynes R.O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* 69, 11-25.
- Hynes R.O., Ali I.U., Destree A.T., Mautner V., Perkins M.E., Senger D.R., Wagner D.D. and Smith K.K. (1978). A large glycoprotein lost from the surfaces of transformed cells. *Ann. NY Acad. Sci.* 312, 317-342.
- Ibrahim S.N., Lightner V.A., Ventimiglia J.B., Ibrahim G.K., Walther P.J., Bigner D.D. and Humphrey P.A. (1993). Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. *Hum. Pathol.* 24, 982-989.
- Jahkola T., Toivonen T., von Smitten K., Blomqvist C. and Virtanen I. (1996). Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. *Int. J. Cancer. (Pred. Oncol.)* 69, 445-447.
- Jeffers M., Rong S. and Woude G.F.V. (1996). Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. *J. Mol. Med.* 74, 505-513.
- Kaarteenaho-Wiik R., Tani T., Sormunen R., Soini Y., Virtanen I. and Pääkkö P. (1996). Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. *Am. J. Resp. Crit. Care Med.* 154, 511-518.
- Kaczmarek J., Castellani P., Nicolo G., Spina B., Allemanni G. and Zardi L. (1994). Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. *Int. J. Cancer.* 58, 11-16.
- Karavanova I., Dove L., Resau J.H. and Perantoni A.O. (1996). Conditioned medium from a rat ureteric bud cell line in combination with bFGF induces complete differentiation of isolated metanephric mesenchyme. *Development* 122, 4159-4167.
- Katz A., Fish A.J., Kleppel M.M., Hagen S.G., Michael A.F. and Butkowski R.J. (1991). Renal entactin (nidogen): Isolation, characterization and tissue distribution. *Kidney Int.* 40, 643-652.
- Khazaie K., Schirmacher V. and Lichtner R.B. (1993). EGF receptor in neoplasia and metastasis. *Cancer Met. Rev.* 12, 255-274.
- Klein G., Langedegger M., Timpl R. and Ekblom P. (1988). Role of laminin A chain in the development of epithelial cell polarity. *Cell* 55, 331-341.
- Klein G., Ekblom M., Fecker L., Timpl R. and Ekblom P. (1990). Differential expression of laminin A and B chains during development of embryonic mouse organs. *Development* 110, 823-837.
- Kobayashi T., Honke K., Miyazaki T., Matsumoto K., Nakamura T., Ishizuka I. and Makita A. (1994a). Hepatocyte growth factor specifically binds to sulfoglycolipids. *J. Biol. Chem.* 269, 9817-9821.
- Kobayashi T., Honke K., Gasa S., Miyazaki T., Tajima H., Matsumoto K., Nakamura T. and Makita A. (1994b). Hepatocyte growth factor elevates the activity levels of glycolipid sulfotransferases in renal cell

ECM in renal cell carcinomas

- carcinoma cells. *Eur. J. Biochem.* 219, 407-413.
- Kochevar G.J., Stanek J.A. and Rucker E.B. (1992). Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. *Cancer* 69, 2311-2315.
- Korhonen M., Yläne J., Laitinen L. and Virtanen I. (1990a). Distribution of $\beta 1$ and $\beta 3$ integrins in human fetal and adult kidney. *Lab. Invest.* 62, 616-625.
- Korhonen M., Yläne J., Laitinen L. and Virtanen I. (1990b). The $\alpha 1$ - $\alpha 6$ subunits of integrins are characteristically expressed in distinct segments of developing and adult human nephron. *J. Cell Biol.* 111, 1245-1254.
- Korhonen M., Laitinen L., Yläne J., Gould V.E. and Virtanen I. (1992a). Integrins in developing, normal and malignant human kidney. *Kidney Int.* 41, 641-644.
- Korhonen M., Laitinen L., Yläne J., Koukoulis G.K., Quaranta V., Juusela H., Gould V.E. and Virtanen I. (1992b). Integrin distributions in renal cell carcinomas of various grades of malignancy. *Am. J. Pathol.* 141, 1161-1171.
- Koukoulis G.K., Gould V.E., Bhattacharyya A., Gould J.E., Howedy A.A. and Virtanen I. (1991). Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. *Hum. Pathol.* 22, 636-643.
- Koukoulis G.K., Shen J., Virtanen I. and Gould V.E. (1995). Immunolocalization of cellular fibronectins in the normal liver, cirrhosis, and hepatocellular carcinoma. *Ultrastruct. Pathol.* 19, 37-43.
- Kovacs G. (1989). Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. *Am. J. Pathol.* 134, 27-34.
- Kreidberg J.A., Donovan M.J., Goldstein S.L., Renne H., Shepherd K., Jones R.C. and Jaenisch R. (1996). $\alpha 3\beta 1$ integrin has a crucial role in kidney and lung organogenesis. *Development* 122, 3537-3547.
- Laitinen L., Vartio T. and Virtanen I. (1991). Cellular fibronectins are differentially expressed in human fetal and adult kidney. *Lab. Invest.* 64, 492-498.
- Liotta L.A. and Stetler-Stevenson W.G. (1990). Metalloproteinases and cancer invasion. *Semin. Cancer Biol.* 1, 99-106.
- Liotta L.A. and Stetler-Stevenson W.G. (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. *Cancer Res.* 51, 5054-5059.
- Lohi J., Tani T., Laitinen L., Kangas L., Lehto V.-P. and Virtanen I. (1995). Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. *Int. J. Cancer* 63, 442-449.
- Lohi J., Leivo I., Tani T., Kiviluoto T., Kivilaakso E., Burgeson R.E. and Virtanen I. (1996a). Laminins, tenascin and type VII collagen in colorectal mucosa. *Histochem. J.* 28, 431-440.
- Lohi J., Tani T., Leivo I., Linnala A., Kangas L., Burgeson R.E., Lehto V.-P. and Virtanen I. (1996b). Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. *Int. J. Cancer* 68, 364-371.
- Lohi J., Korhonen M., Leivo I., Kangas L., Tani T., Kalluri R., Miner J.H., Lehto V.-P. and Virtanen I. (1997a). Expression of type IV collagen $\alpha 1(IV)$ - $\alpha 6(IV)$ polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocyotomas. *Int. J. Cancer* 72, 43-49.
- Lohi J., Leivo I., Franssila K. and Virtanen I. (1997b). Changes in the distribution of integrins and their basement membrane ligands during development of human thyroid follicular epithelium. *Histochem. J.* 29, 337-345.
- Magro G., Grasso S., Colombatti A. and Lopes M. (1996). Immunohistochemical distribution of type VI collagen in developing human kidney. *Histochem. J.* 28, 385-390.
- Magro G., Grasso S., Colombatti A., Villari L. and Emmanuelle C. (1995). Distribution of extracellular matrix glycoproteins in the human mesonephros. *Acta Histochem.* 97, 343-351.
- Mancilla-Jimenez R., Stanley R.J. and Blath R.A. (1976). Papillary renal cell carcinoma. A clinical, radiologic, and pathologic study of 34 cases. *Cancer* 38, 2469-2480.
- Mårtensson S., Brunmark C., Ohlsson L., Bak-Jensen E., Butkowski R., Boketoft Å. and Wieslander J. (1995). Heterogeneity of renal carcinoma. *Nephrol. Dial. Transplant.* 10, 1637-1643.
- Martin M., Pujuguet P. and Martin M. (1996). Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. *Pathol. Res. Pract.* 192, 712-717.
- Matsumoto K., Saga Y., Ikemura T., Sakakura T. and Chiquet-Ehrismann R. (1994). The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. *J. Cell Biol.* 125, 483-493.
- Matsuura H., Greene T. and Hakomori S.-I. (1989). An α -N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. *J. Biol. Chem.* 264, 10472-10476.
- Mercurio A. (1995). Laminin receptors: achieving specificity through cooperation. *Trends Cell Biol.* 5, 419-423.
- Merker H.J. (1994). Morphology of the basement membrane. *Microsc. Res. Techn.* 28, 95-124.
- Miner J.H. and Sanes J.R. (1994). Collagen IV $\alpha 3$, $\alpha 4$, and $\alpha 5$ chains in rodent basal laminae: sequence, distribution, association with laminins and developmental switches. *J. Cell Biol.* 127, 879-891.
- Miner J.H., Patton B.L., Lentz S.I., Gilbert D.J., Snider W.D., Jenkins N.A., Copeland N.G. and Sanes J.R. (1997). The laminin α chains: expression, developmental transitions, and chromosomal locations of $\alpha 1$ -5, identification of heterotrimeric laminins 8-11, and cloning of a novel $\alpha 3$ isoform. *J. Cell Biol.* 137, 685-701.
- Miyake H., Hara I., Yoshimura K., Eto H., Arakawa S., Chihara K. and Kamidono S. (1996). Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. *Cancer Res.* 56, 2440-2445.
- Moch H., Torhorst J., Durmuller U., Feichter G.E., Sauter G. and Gudat F. (1993). Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. *Pathol. Res. Pract.* 189, 510-514.
- Motzer R.J., Bander N.H. and Nanus D.M. (1996). Renal-cell carcinoma. *New Engl. J. Med.* 335, 865-875.
- Murata J., Saiki I., Yoneda J. and Azuma I. (1992). Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. *Jpn. J. Cancer Res.* 83, 1327-1333.
- Nanus D.M., Schmitz-Drager B.J., Motzer R.J., Lee A.C., Vlamis V., Cordon-Cardo C., Albino A.P. and Reuter V.E. (1993). Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. *J. Natl. Cancer Inst.* 85, 1597-1599.
- Natali P.G., Nicotra M.R., Bigotti A., Botti C., Castellani P., Risso A.M. and Zardi L. (1991). Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. *Int. J. Cancer* 47, 811-816.
- Natali P.G., Prat M., Nicotra M.R., Bigotti A., Olivero M., Comoglio M. and Renzo M.F.D. (1996). Overexpression of the met/HGF receptor in renal cell carcinomas. *Int. J. Cancer. (Pred. Oncol.)* 69, 212-217.
- Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F. and Folkman J. (1994). Elevated levels of an angiogenic peptide, basic

ECM in renal cell carcinomas

- fibroblast growth factor, in the urine of patients with a spectrum of cancers. *J. Natl. Cancer Inst.* 86, 356-361.
- Niessen C.M., Hogervorst F., Jaspars L.H., Melker A.A., Delwel G.O., Hulsman E.H.M., Kuikman I. and Sonnenberg A. (1994). The $\alpha 6 \beta 4$ integrin is a receptor for both laminin and kalinin. *Exp. Cell Res.* 211, 360-367.
- Ninomiya Y., Kagawa M., Iyama K.-I., Naito I., Kishiro Y., Seyer J.M., Sugimoto M., Oohashi T. and Sado Y. (1995). Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. *J. Cell Biol.* 130, 1219-1229.
- Noakes P.G., Miner J.H., Gautam M., Gunningham J.M., Sanes J.R. and Merlie J.P. (1995). The renal glomerulus of mice lacking s-laminin/laminin $\beta 2$: nephrosis despite molecular compensation by laminin $\beta 1$. *Nature Genetics.* 10, 400-406.
- Olive D., Lopez M., Maraninchi D., Blaise D., Viens P. and Brandely M. (1991). Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemia blasts after *in vivo* administration of high dose recombinant interleukin-2. *J. Immunother.* 10, 412-417.
- Oosterwijk E., Ruiter D.J., Wakka J.C., Huiskens-van der Meij J.W., Jonas U., Fleuren G.J., Zwartendijk J., Hoedemaeker P. and Warnaar S.O. (1986). Immunohistochemical analysis of monoclonal antibodies to renal antigens: Application in the diagnosis of renal cell carcinoma. *Am. J. Pathol.* 123, 301-309.
- Oosterwijk E., van Muijen G.N.P., Oosterwijk-Wakka J.C. and Warnaar S.O. (1990). Expression of intermediate filaments in developing and adult human kidney and in renal cell carcinoma. *J. Histochem. Cytochem.* 38, 385-392.
- Patey N., Halbwachs-mecarelli L., Droz D., Lesavre P. and Noel L.H. (1994). Distribution of integrin subunits in normal human kidney. *Cell Adh. Communic.* 2, 159-167.
- Paulsson M., Deutzmann R., Dziadek M., Nowack H., Timpl R., Weber S. and Engel J. (1986). Purification and structural characterization of intact and fragmented nidogen obtained from a tumor basement membrane. *Eur. J. Biochem.* 156, 467-478.
- Peissel B., Geng L., Kalluri R., Kashtan C., Rennke H.G., Gallo G.R., Yoshioka K., Sun M.J., Hudson B.G., Nielson E.G. and Zhou J. (1995). Comparative distribution of the $\alpha 1(IV)$, $\alpha 5(IV)$ and $\alpha 6(IV)$ collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. *J. Clin. Invest.* 96, 1948-1957.
- Plateroti M., Freund J.-N., Leberquier C. and Keding M. (1997). Mesenchyme-mediated effects of retinoic acid during rat intestinal development. *J. Cell. Sci.* 110, 1227-1238.
- Price J.T., Wilson H.M. and Haites N.E. (1996). Epidermal growth factor (EGF) increases the *in vitro* invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. *Eur. J. Cancer* 11, 1977-1982.
- Rabb H., Barroso-Vicens E., Adams R., Pow-Sang J. and Ramirez G. (1996). Alpha-V/Beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. *Am. J. Nephrol.* 16, 402-408.
- Ramp U., Jaquet K., Reinecke P., Nitsch T., Gabbert H.E. and Gerharz C.D. (1997). Acquisition of TGF- $\beta 1$ resistance: an important progression factor in human renal cell carcinoma. *Lab. Invest.* 76, 739-749.
- Reddy K.B., Hocevar B.A. and Howe P.H. (1994). Inhibition of G1 phase cyclin dependent kinases by transforming growth factor $\beta 1$. *J. Cell. Biochem.* 56, 418-425.
- Ruoslahti E. (1991). Integrins. *J. Clin. Invest.* 87, 1-5.
- Saga Y., Yagi T., Ikawa Y., Sakakura T. and Aizawa S. (1992). Mice develop normally without tenascin. *Genes Dev.* 6, 1821-1831.
- Santos O.F.P., Barros E.J.G., Yang X.-M., Matsumoto K., Nakamura T., Park M. and Nigam S.K. (1994). Involvement of hepatocyte growth factor in kidney development. *Dev. Biol.* 163, 525-529.
- Schwartz M.A., Schaller M.D. and Ginsberg M.H. (1995). INTEGRINS: Emerging paradigms of signal transduction. *Annu. Rev. Cell Dev. Biol.* 11, 549-599.
- Senger D.R., Van De Water L., Brown L.F., Nagy J.A., Yeo K.-T., Yeo T.-K., Berse B., Jackman R.W., Dvorak A.M. and Dvorak H.F. (1993). Vascular permeability factor (VPF, VEGF) in tumor biology. *Cancer Metast. Rev.* 12, 303-324.
- Shoji T., Kamiya T., Tsubura A., Hamada Y., Hatono T., Hioki K. and Morii S. (1993). Tenascin staining positivity and the survival of patients with invasive breast carcinoma. *J. Surg. Res.* 55, 295-297.
- Simon E.E. and McDonald J.A. (1990). Extracellular matrix receptors in the kidney cortex. *Am. J. Physiol.* 259, F783-F792.
- Soini Y., Pääkkö P., Virtanen I. and Lehto V.P. (1992). Tenascin in salivary gland tumours. *Virchows Arch. (A)* 421, 217-222.
- Sorokin L.M., Conzelmann S., Ekblom P., Battaglia C., Aumailley M. and Timpl R. (1992). Monoclonal antibodies against laminin A chain fragment E3 and their effects on binding to cells and proteoglycan and on kidney development. *Exp. Cell Res.* 201, 137-144.
- Sorokin L., Sonnenberg A., Aumailley M., Timpl R. and Ekblom P. (1990). Recognition of the laminin E8 cell-binding site by an integrin possessing the $\alpha 6$ subunit is essential for epithelial polarization in developing kidney tubules. *J. Cell Biol.* 111, 1265-1273.
- Streit M., Schmidt R., Hilgenfeld R.U., Thiel E. and Kreuser E.D. (1996). Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. *J. Mol. Med.* 74, 253-268.
- Taipale J. and Keski-Oja J. (1997). Growth factors in the extracellular matrix. *FASEB J.* 11, 51-59.
- Terpe H.J., Tajrobehkar K., Gunthert U. and Altmannsborg M. (1993). Expression of cell adhesion molecules alpha-2, alpha-5 and alpha-6 integrin, E-cadherin, N-CAM and CD-44 in renal cell carcinomas: An immunohistochemical study. *Virchows Arch. (A)* 422, 219-224.
- Thomas T. and Dziadek M. (1993). Differential expression of laminin, Nidogen and collagen IV genes in the midgestation mouse placenta. *Placenta* 14, 701-713.
- Tiitta O., Wahlström T., Paavonen J., Linnala A., Sharma S., Gould V.E. and Virtanen I. (1992). Enhanced tenascin expression in cervical and vulvar coliocytic lesions. *Am. J. Pathol.* 141, 907-913.
- Tiitta O., Wahlström T., Virtanen I. and Gould V.E. (1993). Tenascin in inflammatory conditions and neoplasms of the urinary bladder. *Virchows Arch. (B)* 63, 283-287.
- Tiitta O., Happonen R.P., Virtanen I. and Luomanen M. (1994). Distribution of tenascin in oral premalignant lesions and squamous cell carcinoma. *J. Oral Pathol.* 23, 446-450.
- Timpl R. and Brown J.C. (1996). Supramolecular assembly of basement membranes. *Bioessays* 18, 123-132.
- Timpl R., Dziadek M., Fujiwara S., Nowack H. and Wick G. (1983). Nidogen: A new self-aggregating basement membrane protein. *Eur. J. Biochem.* 137, 455-465.
- Timpl R., Rhode H., Robey P.G., Rennard S.I., Foidart J.M. and Martin G.R. (1979). Laminin - A glycoprotein from basement membranes. *J. Biol. Chem.* 254, 9933-9937.
- Tomita Y., Toshiro S., Saito K., Oite T., Shimizu F. and Shotaro S. (1995). Possible significance of VLA-4 ($\alpha 4 \beta 1$) for hematogenous

ECM in renal cell carcinomas

- metastasis of renal-cell cancer. *Int. J. Cancer* 60, 753-758.
- Truong L.D., Foster S.V., Barrios R., D'Agati V., Verani R.R., Gonzalez J.M. and Suki W.N. (1996). Tenascin is an ubiquitous extracellular matrix protein of human renal interstitium in normal and pathologic conditions. *Nephron* 72, 579-586.
- Truong L.D., Pindur J., Barrios R., D'Agati V., Lechago J. and Majesky M. (1994). Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. *Kidney Int.* 45, 201-210.
- Underhill C. (1992). CD44: the hyaluron receptor. *J. Cell Sci.* 103, 293-298.
- Vaheri A. and Mosher D.F. (1978). High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in malignant transformation. *Biochem. Biophys. Acta* 516, 1-35.
- Vaheri A. and Ruoslahti E. (1974). Disappearance of major cell-type specific surface glycoprotein antigen (SF) after transformation of fibroblasts by rous sarcoma virus. *Int. J. Cancer* 13, 579-586.
- Varner J.A. and Cheres D.A. (1996). Integrins and cancer. *Curr. Opin. Cell Biol.* 8, 724-730.
- Virtanen I., Laitinen L. and Korhonen M. (1995). Differential expression of laminin polypeptides in developing and adult human kidney. *J. Histochem. Cytochem.* 43, 621-628.
- Virtanen I., Lohi J., Tani T., Sariola H., Burgeson R.E. and Lehto V.P. (1996). Laminin chains in the basement membranes of human thymus. *Histochem. J.* 28, 643-650.
- Virtanen I., Lohi J., Tani T., Korhonen M., Burgeson R.E., Lehto V.P. and Leivo I. (1997). Distinct changes in the laminin composition of basement membranes in human seminiferous tubules during development and degeneration. *Am. J. Pathol.* 150, 1421-1431.
- Wade T.P., Kasid A., Stein C.A., LaRocca R.V., Sargent E.R., Gomella L.G., Myers C.E. and Linehan W.M. (1992). Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. *J. Surg. Res.* 53, 195-198.
- Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C. and Bissel M.J. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and *in vivo* by integrin blocking antibodies. *J. Cell Biol.* 137, 231-245.
- Weiss L.M., Gelb A.B. and Medeiros J. (1995). Adult renal epithelial neoplasms. *Am. J. Clin. Pathol.* 103, 624-635.
- Wernert N. (1997). The multiple roles of tumour stroma. *Virchows Arch.* 430, 433-443.
- Wetzels R.H.W., Robben H.C.M., Leigh I.M., Schaafsma H.E., Vooijs G.P. and Ramaekers F.C.S. (1991). Distribution patterns of type VII collagen in normal and malignant human tissues. *Am. J. Pathol.* 139, 451-459.
- Woolf A.S., Kolatsi-Joannou M., Hardman P., Andermarcher E., Moorby C., Fine L.G., Jat P.S., Noble M.D. and Gherardi E. (1995). Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. *J. Cell Biol.* 128, 171-184.
- Yanase Y., Tsukamoto T. and Kumamoto Y. (1995). Cytokines modulate *in vitro* invasiveness of renal cell carcinoma cells through action on the process of cell attachment to endothelial cells. *J. Urol.* 153, 844-848.
- Yang A.H., Chiang H. and Liu H.C. (1990). Invasiveness of renal cell carcinoma - An *in vitro* model. *Exp. Mol. Pathol.* 53, 191-202.
- Yoshioka K., Hino S., Takemura T., Maki S., Wieslander J., Takekoshi Y., Makino H., Kagawa M., Sado Y., Kashtan C.E. (1994). Type IV collagen $\alpha 5$ chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. *Am. J. Pathol.* 144, 986-996.
- Yeo T.-K. and Dvorak H.F. (1995). Tumor stroma. In: *Diagnostic immunopathology*. 2nd ed. Colvin R.B., Bhan A.K. and McCluskey R.T. (eds). Raven Press. New York. pp 685-697.
- Zhang K. and Kramer R.H. (1996). Laminin 5 deposition promotes keratinocyte motility. *Exp. Cell Res.* 227, 309-322.